Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

982 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges.
Working Group on the Summit on Combination Therapy for CVD; Yusuf S, Attaran A, Bosch J, Joseph P, Lonn E, McCready T, Mente A, Nieuwlaat R, Pais P, Rodgers A, Schwalm JD, Smith R, Teo K, Xavier D. Working Group on the Summit on Combination Therapy for CVD, et al. Among authors: teo k. Eur Heart J. 2014 Feb;35(6):353-64. doi: 10.1093/eurheartj/eht407. Epub 2013 Nov 27. Eur Heart J. 2014. PMID: 24288261 Review.
Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease.
Anand SS, Yi Q, Gerstein H, Lonn E, Jacobs R, Vuksan V, Teo K, Davis B, Montague P, Yusuf S; Study of Health Assessment and Risk in Ethnic Groups; Study of Health Assessment and Risk Evaluation in Aboriginal Peoples Investigators. Anand SS, et al. Among authors: teo k. Circulation. 2003 Jul 29;108(4):420-5. doi: 10.1161/01.CIR.0000080884.27358.49. Epub 2003 Jul 14. Circulation. 2003. PMID: 12860914
Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B, Hilbrich L, Pogue J, Schumacher H; ONTARGET/TRANSCEND Investigators. Teo K, et al. Am Heart J. 2004 Jul;148(1):52-61. doi: 10.1016/j.ahj.2004.03.020. Am Heart J. 2004. PMID: 15215792 Clinical Trial.
Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: results from the ONTARGET/TRANSCEND research programme.
Cukierman-Yaffe T, Gerstein HC, Anderson C, Zhao F, Sleight P, Hilbrich L, Jackson SH, Yusuf S, Teo K; ONTARGET/TRANSCEND Investigators. Cukierman-Yaffe T, et al. Among authors: teo k. Diabetes Res Clin Pract. 2009 Mar;83(3):387-93. doi: 10.1016/j.diabres.2008.12.005. Epub 2009 Jan 20. Diabetes Res Clin Pract. 2009. PMID: 19157618
The cardiac MRI substudy to ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease: analysis protocol and baseline characteristics.
Cowan BR, Young AA, Anderson C, Doughty RN, Krittayaphong R, Lonn E, Marwick TH, Reid CM, Sanderson JE, Schmieder RE, Teo K, Wadham AK, Worthley SG, Yu CM, Yusuf S, Jennings GL. Cowan BR, et al. Among authors: teo k. Clin Res Cardiol. 2009 Jul;98(7):421-33. doi: 10.1007/s00392-009-0014-4. Epub 2009 Apr 4. Clin Res Cardiol. 2009. PMID: 19347385 Clinical Trial.
The Family Atherosclerosis Monitoring In earLY life (FAMILY) study: rationale, design, and baseline data of a study examining the early determinants of atherosclerosis.
Morrison KM, Atkinson SA, Yusuf S, Bourgeois J, McDonald S, McQueen MJ, Persadie R, Hunter B, Pogue J, Teo K; FAMILY investigators. Morrison KM, et al. Among authors: teo k. Am Heart J. 2009 Oct;158(4):533-9. doi: 10.1016/j.ahj.2009.07.005. Epub 2009 Aug 28. Am Heart J. 2009. PMID: 19781411
982 results